USA flag logo/image

An Official Website of the United States Government

ANTIBODIES TO ATRIAL PEPTIDE RECEPTOR

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
11457
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
11457
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
California Biotechnology, Inc.
2450 Bayshore Parkway Mountain View, CA 94043
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1990
Title: ANTIBODIES TO ATRIAL PEPTIDE RECEPTOR
Agency: HHS
Contract: N/A
Award Amount: $490,968.00
 

Abstract:

ATRIAL NATRIURETIC PEPTIDE (ANP) BINDS TO MULTIPLE CELL SURFACE RECEPTORS IN A NUMBER OF DIFFERENT TISSUES, RESULTING IN EFFECTS RELATED TO CARDIOVASCULAR HOMEOSTASIS. THIS RESEARCH INVOLVES THE GENERATION OF SPECIFIC ANTIBODIESTO A CLONED ANP RECEPTOR THAT APPEARS TO FUNCTION IN THE METABOLIC CLEARANCE OF ANP. SPECIFICALLY, IT IS PLANNED TO USE A RECOMBINANT VACCINIA VIRUS EXPRESSING CLONED RECEPTOR SEQUENCES TO GENERATE ANP-RECEPTOR-SPECIFIC ANTISERA. THE RECEPTOR, TERMED THE C-ANP RECEPTOR, IS A THERAPEUTICALLY IMPORTANT TARGET BECAUSE ANP ANALOGS THAT BIND TO THIS RECEPTOR LEAD TO AN INCREASE IN ENDOGENOUS ANP LEVELS. POLYCLONAL AND MONOCLONAL ANTIBODIES THAT CAN BIND TO THIS SPECIFIC CLASS OF RECEPTORS AND/OR INHIBIT THE LIGAND-RECEPTOR INTERACTION WILL BE VALUABLE IN DISCERNING THE PHYSIOLOGICAL ROLE, TISSUE DISTRIBUTION, AND MOLECULAR ARCHITECTURE OF THE ANP RECEPTOR UNDER VARIOUS NORMAL AND PATHOLOGIC CONDITIONS. IN ADDITION, THE ANTIBODIES WILL BE IMPORTANT TOOLS TO AID IN THE DESIGN OF THERAPEUTIC AGENTS THAT INTERACT WITH THIS RECEPTOR.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

California Biotechnology Inc.
2450 Bayshore Frontage Rd Mountain View, CA 94043

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No